Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers
Successful clinical methods for tumor elimination include a combination of surgical resection, radiotherapy, and chemotherapy. Radiotherapy is one of the crucial components of the cancer treatment regimens which allow to extend patient life expectancy. Current cutting-edge radiotherapy research is focused on the identification of methods that should increase cancer cell sensitivity to radiation and activate anti-cancer immunity mechanisms. Radiation treatment activates various cells of the tumor microenvironment (TME) and impacts tumor growth, angiogenesis, and anti-cancer immunity. Radiotherapy was shown to regulate signaling and anti-cancer functions of various TME immune and vasculature cell components, including tumor-associated macrophages, dendritic cells, endothelial cells, cancer-associated fibroblasts (CAFs), natural killers, and other T cell subsets. Dual effects of radiation, including metastasis-promoting effects and activation of oxidative stress, have been detected, suggesting that radiotherapy triggers heterogeneous targets. In this review, we critically discuss the activation of TME and angiogenesis during radiotherapy which is used to strengthen the effects of novel immunotherapy. Intracellular, genetic, and epigenetic mechanisms of signaling and clinical manipulations of immune responses and oxidative stress by radiotherapy are accented. Current findings indicate that radiotherapy should be considered as a supporting instrument for immunotherapy to limit the cancer-promoting effects of TME. To increase cancer-free survival rates, it is recommended to combine personalized radiation therapy methods with TME-targeting drugs, including immune checkpoint inhibitors.
Top-30
Journals
|
1
|
|
|
Frontiers in Immunology
1 publication, 7.69%
|
|
|
Cancer Letters
1 publication, 7.69%
|
|
|
Biological Procedures Online
1 publication, 7.69%
|
|
|
Journal of Clinical Medicine
1 publication, 7.69%
|
|
|
Journal of Hepatocellular Carcinoma
1 publication, 7.69%
|
|
|
Critical Reviews in Oncology/Hematology
1 publication, 7.69%
|
|
|
Cancer Innovation
1 publication, 7.69%
|
|
|
International Journal of Molecular Sciences
1 publication, 7.69%
|
|
|
Nanoscale
1 publication, 7.69%
|
|
|
PLoS Computational Biology
1 publication, 7.69%
|
|
|
Clinical and Experimental Metastasis
1 publication, 7.69%
|
|
|
Chemical Engineering Journal
1 publication, 7.69%
|
|
|
1
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 23.08%
|
|
|
Springer Nature
2 publications, 15.38%
|
|
|
MDPI
2 publications, 15.38%
|
|
|
Frontiers Media S.A.
1 publication, 7.69%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 7.69%
|
|
|
Taylor & Francis
1 publication, 7.69%
|
|
|
Wiley
1 publication, 7.69%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 7.69%
|
|
|
Public Library of Science (PLoS)
1 publication, 7.69%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.